Stijn W. van Beek

Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Saskia C. van der Boor, Merel Smit, Stijn W. van Beek et al. · The Lancet Infectious Diseases · 2022 · 41 citations · Full text

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

Stijn W. van Beek, Rob ter Heine, Ron J. Keizer et al. · Clinical Pharmacokinetics · 2019 · 22 citations · Full text

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Precious Ngwalero, James C.M. Brust, Stijn W. van Beek et al. · Antimicrobial Agents and Chemotherapy · 2021 · 21 citations · Full text

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

David W. Haas, Mahmoud Tareq Abdelwahab, Stijn W. van Beek et al. · The Journal of Infectious Diseases · 2022 · 19 citations · Full text

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept

Stan J. F. Hartman, Joost G. E. Swaving, Stijn W. van Beek et al. · Frontiers in Pharmacology · 2020 · 13 citations · Full text